Please login to the form below

Not currently logged in

Galapagos and Janssen end inflammation alliance

Galapagos regains right to GLPG1690

GalapagosJanssen and Galapagos have mutually agreed to terminate their inflammation alliance and option agreements. 

Alongside other candidates, Galapagos will obtain all rights to drug GLPG1690, a selective autotaxin inhibitor preparing for phase II clinical trial in idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterised by a progressive decline in lung function. 

Dr Piet Wigerinck, chief scientific officer at Galapagos, commented: “We are pleased to regain the rights to GLPG1690 to pursue the most suitable clinical application of autotaxin inhibition. 

“The alliance with Janssen has been underway since October 2007 and has generated three clinical molecules, two of which are now proprietary phase II assets of Galapagos: GLPG1205 and GLPG1690. This programme is a valuable component of our development portfolio and regaining the rights is a next step in our transformation into a mature biotech company with a proprietary product pipeline.”

Galapagos identified autotaxin as having a key role to play in inflammation with additional studies suggesting it may also be significant against metabolic disease, arthritic pain, oncology and lung disease. 

Article by
Kirstie Pickering

18th March 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....